Cargando…

Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma

BACKGROUND: Malignant mesothelioma is an aggressive cancer and has a poor prognosis. Here, we analyzed the feasibility, molecular and gender aspects of targeted therapy recommendations for malignant mesothelioma based on the individual molecular tumor profile. METHODS: In this single‐center, real‐wo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taghizadeh, Hossein, Zöchbauer‐Müller, Sabine, Mader, Robert M., Müllauer, Leonhard, Klikovits, Thomas, Bachleitner‐Hofmann, Thomas, Hoda, Mir A., Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327667/ https://www.ncbi.nlm.nih.gov/pubmed/32438515 http://dx.doi.org/10.1111/1759-7714.13491

Ejemplares similares

Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Molecularly guided treatment of metastatic parotid gland carcinoma in adults
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Applied precision cancer medicine in metastatic biliary tract cancer
por: Taghizadeh, H., et al.
Publicado: (2020)

Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Geltner, Christian, et al.
Publicado: (2016)

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin
por: Ries, Alexander, et al.
Publicado: (2023)

Management of malignant pleural mesothelioma – part 3: Data from the Austrian Mesothelioma Interest Group (AMIG) database
por: Klikovits, Thomas, et al.
Publicado: (2016)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort
por: Steindl, Ariane, et al.
Publicado: (2019)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case
por: Hoda, Mir Alireza, et al.
Publicado: (2018)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients
por: Taghizadeh, Hossein, et al.
Publicado: (2023)

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
por: Mosleh, Berta, et al.
Publicado: (2023)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
por: Klikovits, Thomas, et al.
Publicado: (2017)

Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases
por: Steindl, Ariane, et al.
Publicado: (2020)

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma – an Austrian expert consensus statement
por: Taghizadeh, Hossein, et al.
Publicado: (2023)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Metastatic mesothelioma to the thyroid
por: Rao, Sarika N., et al.
Publicado: (2014)

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology
por: Prager, Gerald W., et al.
Publicado: (2019)

Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells
por: Ries, Alexander, et al.
Publicado: (2023)

Next generation sequencing: clinical applications in solid tumours
por: Müllauer, Leonhard
Publicado: (2017)

Milestones in pathology—from histology to molecular biology
por: Müllauer, Leonhard
Publicado: (2017)

Molecular Pathology of Cancer: The Past, the Present, and the Future
por: Müllauer, Leonhard
Publicado: (2021)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Surgical Complexity and Outcome During the Implementation Phase of a Robotic Colorectal Surgery Program—A Retrospective Cohort Study
por: Müller, Catharina, et al.
Publicado: (2021)

Applied Precision Cancer Medicine in Neuro-Oncology
por: Taghizadeh, H., et al.
Publicado: (2019)

The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure
por: Marinaccio, Alessandro, et al.
Publicado: (2018)

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers
por: Altenberger, Corinna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d3rpmu4pkh5c71dn6la4kkln0g